Evidence-based public policy making for medicines across countries; findings and implications for the future

Brian Godman, Joseph Fadare, Hye-Young Kwon, Carolina Zampirolli Dias, Amanj Kurdi, Isabella Piassi Godói, Dan Kibuule, Iris Hoxha, Sylvia Opanga, Zikria Saleem, Tomasz Bochenek, Vanda Marković-Peković, Ileana Mardare, Aubrey C Kalungia, Stephen Campbell, Eleonora Allocati, Alice Pisana, Antony P Martin, Johanna C Meyer

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-communicable diseases (NCDs) and new premium priced medicines for cancer, orphan diseases and other complex areas. This is difficult to sustain without reforms. Extensive narrative review of published papers and contextualizing the findings to provide future guidance. New models are being introduced to improve the managed entry of new medicines including managed entry agreements, fair pricing approaches and monitoring prescribing against agreed guidance. Multiple measures have also successfully been introduced to improve the prescribing of established medicines. This includes encouraging greater prescribing of generics and biosimilars versus originators and patented medicines in a class to conserve resources without compromising care. In addition, reducing inappropriate antibiotic utilization. Typically, multiple measures are the most effective. Multiple measures will be needed to attain and retain universal healthcare.
Original languageEnglish
Pages (from-to)1019-1052
Number of pages34
JournalJournal of Comparative Effectiveness Research
Volume10
Issue number12
Early online date9 Jul 2021
DOIs
Publication statusPublished - 31 Aug 2021

Keywords

  • antimicrobials
  • biosimilars
  • Covid-19
  • demand-side measures
  • generics
  • guidelines
  • managed entry
  • orphan medicines
  • oncology
  • quality indicators
  • statins

Fingerprint

Dive into the research topics of 'Evidence-based public policy making for medicines across countries; findings and implications for the future'. Together they form a unique fingerprint.

Cite this